Citations

Showing 10 of 108162 citations.

Validation of the Personality Assessment Inventory (PAI) scale of scales in a mixed clinical sample
Boress, Kaley , Gaasedelen, Owen J., Croghan, Anna, Johnson, Marcie King, Caraher, Kristen , Basso, Michael R. , Whiteside, Douglas M. , Whiteside, Douglas

Mayo Clinic

The Clinical Neuropsychologist | March 18, 2021 | Volume: 36 | Issue: 7 | Pages: 1844-1859

10.1080/13854046.2021.1900400 | PMID 33730975 Get It

Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia
Kamboj, Amrit K. , Gibbens, Ying , Hagen, Catherine E. , Wang, Kenneth K, Iyer, Prasad G. , Katzka, David A. , Gibbens, Ying Y, Hagen, Catherine E

Mayo Clinic

American Journal of Gastroenterology | March 18, 2021 | Volume: 116 | Issue: 7 | Pages: 1533-1536

10.14309/ajg.0000000000001225 | PMID 33734117 Get It

INTRODUCTION: Esophageal epidermoid metaplasia (EEM) is a rare disease. METHODS: Patients with EEM diagnosed between 2014 and 2020 were reviewed. RESULTS: Forty EEM cases were identified. EEM occurred in 9 (23%) patients before, concordant, or after esophageal squamous cell carcinoma (ESCC). EEM was associated with previous esophageal lichen planus in 5 patients, Barrett's esophagus 7, and esophageal adenocarcinoma 1. EEM was focal in 28 (70%) or diffuse in 12 (30%) and not detected in 45% on recent previous endoscopy. DISCUSSION: EEM is a premalignant underrecognized condition associated with multiple conditions. Close follow-up or endoscopic treatment may be warranted because of its ESCC association.
The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis
Cheah, Ramsah, Chirnaksorn, Supphamat , Abdelrahim, Ahmed H., Horgan, Laura, Capstick, Toby , Casey, John , Peckham, D. , Boland, Alison, Sutherland, Timothy J. T., Beirne, Paul , Lee, Augustine S. , DeVault, Kenneth R. , Houghton, Lesley A. , Houghton, L A , Sutherland, Tim

Mayo Clinic

American Journal of Gastroenterology | March 18, 2021 | Volume: 116 | Issue: 6 | Pages: 1189-1200

10.14309/ajg.0000000000001202 | PMID 34074825 Get It

INTRODUCTION: Gastroesophageal reflux plays a significant role in idiopathic pulmonary fibrosis (IPF). Given the morbidity and mortality associated with IPF, understanding the mechanisms responsible for reflux is essential if patients are to receive optimal treatment and management, especially given the lack of clear benefit of antireflux therapies. Our aim was to understand the inter-relationships between esophageal motility, lung mechanics and reflux (particularly proximal reflux—a prerequisite of aspiration), and pulmonary function in patients with IPF. METHODS: We prospectively recruited 35 patients with IPF (aged 53–75 years; 27 men) who underwent high-resolution impedance manometry and 24-hour pH-impedance, together with pulmonary function assessment. RESULTS: Twenty-two patients (63%) exhibited dysmotility, 16 (73%) exhibited ineffective esophageal motility (IEM), and 6 (27%) exhibited esophagogastric junction outflow obstruction. Patients with IEM had more severe pulmonary disease (% forced vital capacity: P = 0.032) and more proximal reflux ( P = 0.074) than patients with normal motility. In patients with IEM, intrathoracic pressure inversely correlated with the number of proximal events (r = −0.429; P = 0.098). Surprisingly, inspiratory lower esophageal sphincter pressure (LESP) positively correlated with the percentage of reflux events reaching the proximal esophagus (r = 0.583; P = 0.018), whereas in patients with normal motility, it inversely correlated with the bolus exposure time (r = −0.478; P = 0.098) and number of proximal events (r = −0.542; P = 0.056). % forced vital capacity in patients with IEM inversely correlated with the percentage of reflux events reaching the proximal esophagus (r = −0.520; P = 0.039) and inspiratory LESP (r = −0.477; P = 0.062) and positively correlated with intrathoracic pressure (r = 0.633; P = 0.008). DISCUSSION: We have shown that pulmonary function is worse in patients with IEM which is associated with more proximal reflux events, the latter correlating with lower intrathoracic pressures and higher LESPs.
ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes
Alsharhan, Hind , Edmondson, Andrew C. , Daniel, Earnest James Paul , Donald, Tyhiesia, Bakhtiari, Somayeh , Amor, David J. , Jones, Elizabeth A. , Vassallo, Grace , Deb, Wallid , Werners, Arno , Jin, Sheng Chih , Bilgüvar, Kaya , Webster, Richard , Yearwood, Katherine R., Kruer, Michael C. , Raymond, Kimiyo , Bhoj, Elizabeth , Raymond, Kimiyo M, Bhoj, Elizabeth J , Edmondson, Andrew C , Jin, Sheng Chih , He, Miao , Chen, Jie , Vincent, Marie , Cogné, Benjamin , Christodoulou, John , Ng, Bobby G. , Freeze, Hudson H. , Li, Dong , Sobering, Andrew K.

Mayo Clinic

Journal of Inherited Metabolic Disease | March 18, 2021 | Volume: 44 | Issue: 4 | Pages: 1001-1012

10.1002/jimd.12378 | PMID 33734437 Get It

Abstract Pathogenic variants in ALG13 ( ALG13 UDP‐N‐acetylglucosaminyltransferase subunit ) cause an X‐linked congenital disorder of glycosylation (ALG13‐CDG) where individuals have variable clinical phenotypes that include developmental delay, intellectual disability, infantile spasms, and epileptic encephalopathy. Girls with a recurrent de novo c.3013C>T; p.(Asn107Ser) variant have normal transferrin glycosylation. Using a highly sensitive, semi‐quantitative flow injection‐electrospray ionization‐quadrupole time‐of‐flight mass spectrometry (ESI‐QTOF/MS) N‐glycan assay, we report subtle abnormalities in N‐glycans that normally account for <0.3% of the total plasma glycans that may increase up to 0.5% in females with the p.(Asn107Ser) variant. Among our 11 unrelated ALG13‐CDG individuals, one male had abnormal serum transferrin glycosylation. We describe seven previously unreported subjects including three novel variants in ALG13 and report a milder neurodevelopmental course. We also summarize the molecular, biochemical, and clinical data for the 53 previously reported ALG13‐CDG individuals. We provide evidence that ALG13 pathogenic variants may mildly alter N‐linked protein glycosylation in both female and male subjects, but the underlying mechanism remains unclear.
Ideal Body Weight-Based Dosing of Rabbit Antithymocyte Globulin for Cost Minimization in Kidney Transplantation
Bubik, Rachel J. , Peterson, Kristen , Myhre, Laura J., Bernard, Stacy A. , Dean, Patrick G. , May, Heather P. , Peterson, Kristen T, Dean, Patrick, Personett, Heather A. , Bailen, Rachel J

Mayo Clinic

Progress in Transplantation | March 18, 2021 | Volume: 31 | Issue: 2 | Pages: 184-189

10.1177/15269248211003257 | PMID 33733917 Get It

Introduction: Contemporary dosing strategies for rabbit anti-thymocyte globulin (rATG) in kidney transplantation aim to reduce cumulative exposure, minimizing long-term adverse events. The use of ideal body weight-based dosing has been trialed, however concern for increased rejection post-transplant exists due to lower doses of rATG. Research Questions: The primary aim of this study was to compare rejection rates between rATG dosing protocols using actual body weight and ideal body weight and secondarily to evaluate cost savings following protocol implementation. Design: This was a retrospective study surrounding implementation of an ideal body weight-based dosing protocol for rATG. We compared 75 kidney transplant recipients in whom rATG was dosed based on actual body weight (pre-protocol group) to 64 in whom dosing was based on ideal body weight (post-protocol group), following a nine-month washout. Results: The mean cumulative rATG dose in the pre-protocol group was 6.3 mg/kg of actual body weight. When ideal body weight was used in the post-protocol group, the mean dose was 4.5 mg/kg of actual body weight. The rejection rate was 18.7% pre-protocol and 23.4% postprotocol, which did not represent a statistically significant difference (p = 0.491). The actual annual cost savings after protocol implementation exceeded $162,000, approximately $2,500 per patient. Conclusion: Results suggest ideal body weight-based dosing of rATG may reduce exposure and cost, without significantly impacting the risk of rejection in kidney transplant recipients. More studies are needed to confirm these findings.
Comparison of Biliary Drainage Techniques for Malignant Biliary Obstruction
Xie, Jesse J. , Garg, Shashank , Tharian, Benjamin , Inamdar, Sumant , Murad, Mohammad Hassan, Perisetti, Abhilash , Murad, M. Hassan

Mayo Clinic

Journal of Clinical Gastroenterology | March 18, 2021 | Volume: 56 | Issue: 1 | Pages: 88-97

10.1097/mcg.0000000000001512 | PMID 33780212 Get It

Background and Aims: Endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage, and endoscopic ultrasound (EUS)-guided biliary drainage are all established techniques for drainage of malignant biliary obstruction. This network meta-analysis (NMA) was aimed at comparing all 3 modalities to each other. Materials and Methods: Multiple databases were searched from inception to October 2019 to identify relevant studies. All the patients were eligible to receive any one of the 3 interventions. Data extraction and risk of bias assessment was performed using standardized tools. Outcomes of interest were technical success, clinical success, adverse events, and reintervention. Direct meta-analyses were performed using the random-effects model. NMA was conducted using a multivariate, consistency model with random-effects meta-regression. The GRADE approach was followed to rate the certainty of evidence. Results: The final analysis included 17 studies with 1566 patients. Direct meta-analysis suggested that EUS-guided biliary drainage had a lower reintervention rate than ERCP. NMA did not show statistically significant differences to favor any one intervention with certainty across all the outcomes. The overall certainty of evidence was found to be low to very low for all the outcomes. Conclusions: The available evidence did not favor any intervention for drainage of malignant biliary obstruction across all the outcomes assessed. ERCP with or without EUS should be considered first to allow simultaneous tissue acquisition and biliary drainage.
Hyaluronic Acid Filler for Treatment of Metatarsal Fat Pad Atrophy
Ali, Nora S., Hoss, Elika, Kollipara, Ramya, Goldman, Mitchel P.

Mayo Clinic

Dermatologic Surgery | March 18, 2021 | Volume: 47 | Issue: 7 | Pages: 1034-1035

10.1097/dss.0000000000002999 | PMID 33731566 Get It

Staff-Care by Chaplains during COVID-19
Tata, Beba , Nuzum, Daniel , Murphy, Karen, Karimi, Leila , Cadge, Wendy , Tata-Mbeng, Beba Shensi , Murphy, Karen

Mayo Clinic

Journal of Pastoral Care & Counseling: Advancing theory and professional practice through scholarly and reflective publicati | March 18, 2021 | Volume: 75 | Issue: 1_suppl | Pages: 24-29

10.1177/1542305020988844 | PMID 33730921 Get It

The aim of this study was to understand how chaplains delivered spiritual care to staff during the Covid-19 pandemic. The researchers analyzed data collected from an International Survey of Chaplain Activity and Experience during Covid-19 (N = 1657). The findings revealed positive changes that emerged and new practices evolved around the use of technology as useful tools for maintaining contact with staff.
Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior
Huber, Gianna, Ogrodnik, Mikołaj , Wenzel, Jan , Stölting, Ines, Huber, Lukas , Will, Olga, Peschke, Eva , Matschl, Urte , Hövener, Jan‐Bernd , Schwaninger, Markus , Jurk, Diana , Raasch, Walter , Jurk, Diana , Huber, Lukas

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | March 18, 2021 | Volume: 41 | Issue: 9 | Pages: 2356-2369

10.1177/0271678x211003497 | PMID 33730932 Get It

Angiotensin II receptor blockers (telmisartan) prevent rodents from diet-induced obesity and improve their metabolic status. Hyperglycemia and obesity are associated with reduced cerebral blood flow and neurovascular uncoupling which may lead to behavioral deficits. We wanted to know whether a treatment with telmisartan prevents these changes in obesity. We put young mice on high-fat diet and simultaneously treated them with telmisartan. At the end of treatment, we performed laser speckle imaging and magnetic resonance imaging to assess the effect on neurovascular coupling and cerebral blood flow. Different behavioral tests were used to investigate cognitive function. Mice developed diet-induced obesity and after 16, not 8 weeks of high-fat diet, however, the response to whisker pad stimulation was about 30% lower in obese compared to lean mice. Simultaneous telmisartan treatment increased the response again by 10% compared to obese mice. Moreover, telmisartan treatment normalized high-fat diet-induced reduction of cerebral blood flow and prevented a diet-induced anxiety-like behavior. In addition to that, telmisartan affects cellular senescence and string vessel formation in obesity. We conclude, that telmisartan protects against neurovascular unit impairments in a diet-induced obesity setting and may play a role in preventing obesity related cognitive deficits in Alzheimer’s disease.
Manual lymphatic drainage guided by real-time indocyanine green lymphography in breast cancer-related lymphedema
Ciudad, Pedro , Bustos, Samyd S. , Forte, Antonio J. , Huayllani, María T. , Manrique, Oscar J. , Trignano, Emilio , Forte, Antonio Jorge , Bustos, S S , Chen, Hung‐Chi

Mayo Clinic

Archives of Plastic Surgery | March 18, 2021 | Volume: 48 | Issue: 02 | Pages: 239-240

10.5999/aps.2020.01823 | PMID 33765744 Get It